T-cell lymphoblastic leukemias (T-ALLs) arise from the malignant transformation of T cell progenitors. The most common genetic alterations include the activation of the NOTCH pathway, deletions within the CDKN2A locus and chromosomal rearrangements affecting T cell-specific enhancer elements. In addition, alterations in other signal transduction pathways and chromatin remodelers translate into the genetic heterogeneity of the disease. T-ALL accounts for 10%–15% of pediatric and 25% of adult cases. Clinical symptoms include hyperleukocytosis with extramedullary involvement of lymph nodes and other organs, including frequent central nervous system infiltration and occurrence of mediastinal masses arising from the thymus. The outcome of T-ALL patients has improved due to intensified chemotherapy protocols and cure rates of 75% in children and 50% in adults can be achieved. But the prognosis of primary resistant or relapsed T-ALL patients remains poor underlining the need for novel targeted therapy strategies (1).

Many studies focus on the Hedgehog (HH) pathway as suitable target for directed cancer therapies. The Hedgehog pathway is involved in stem cell proliferation, differentiation, and survival. In mammals, the classical canonical Hedgehog pathway can be activated through three different ligands: Sonic Hedgehog (SHH), Desert Hedgehog (DHH), and Indian Hedgehog (IHH), which bind to the transmembrane receptor Patched-1 (PTCH1). Without the presence of ligands, PTCH1 represses activation of the transmembrane protein Smoothened (SMO). Upon HH ligand binding, PTCH1 is internalized, resulting in relief and thus activation of SMO that transduces the signal to the family of Glioma (GLI) zinc finger transcription factors GLI1, GLI2, and GLI3. GLI1 and GLI2 predominantly represent transcriptional activators while GLI3 acts as transcriptional repressor. Furthermore, Suppressor of Fused (SUFU) acts as negative pathway regulator by inhibiting the activation of GLI transcription factors in the absence of HH ligands (2).

In addition to this classical canonical signaling axis, different mechanisms of non-canonical pathway activation have been described leading to activation of the GLI transcription factors independent of Hedgehog family members or PTCH/SMO. Non-canonical HH pathway activation includes Ras-ERK, TGF-β, or PI3K-AKT (3-5).

Aberrant Hedgehog signaling has been described in a broad variety of cancers. Some cancers such as basal cell carcinoma or medulloblastoma show high frequencies of somatic mutations in PTCH1, SMO or SUFU that account for the dysregulation of the pathway. In other cancers, mutations in Hedgehog family members occur only at low frequencies and different mechanisms including enhanced autocrine or paracrine as well as non-canonical pathway activation might account for the dysregulated HH signaling in those cancers (5). The expression of Hedgehog family members could be correlated to the patients’ outcome in a
The Hedgehog pathway is essential for normal T-cell development as was shown using mice with defects in HH family members. Mice lacking PTCH are characterized by a severely affected T-cell development resulting in thymic atrophy and SHH knockout mice have significantly reduced thymocyte levels during development (14,15).

In a recently published preclinical study, Dagklis and colleagues provide evidence that the HH pathway might represent a valuable therapeutic target (7,10-12). Based on promising preclinical data, first clinical studies investigating the therapeutic potential of HH inhibitors in hematological malignancies are ongoing. Encouraging data from a phase II randomized trial of AML and myelodysplastic syndrome (MDS) patients treated with the SMO inhibitor glasdegib were recently presented at the ASH Annual Meeting (13). Several clinical trials using the SMO inhibitor LDE225 are ongoing including a phase I study combining LDE225 with azacitidine or decitabine in myeloid malignancies (NCT02129101). A phase II study with LDE225 in acute leukemia and a phase I study with LDE225 in combination with nilotinib in CML have already been completed but the results are still awaited (NCT01826214 and NCT01456676, respectively) while, disappointingly, a phase II study with GDC-0449 in patients with AML and MDS had to be prematurely terminated due to lower-than-expected efficacy (NCT01880437).

The Hedgehog pathway is essential for normal T-cell development as was shown using mice with defects in HH family members. Mice lacking PTCCH are characterized by a severely affected T-cell development resulting in thymic atrophy and SHH knockout mice have significantly reduced thymocyte levels during development (14,15).

In a recently published preclinical study, Dagklis and colleagues provide evidence that the HH pathway might represent a valuable therapeutic target (7,10-12). Based on promising preclinical data, first clinical studies investigating the therapeutic potential of HH inhibitors in hematological malignancies are ongoing. Encouraging data from a phase II randomized trial of AML and myelodysplastic syndrome (MDS) patients treated with the SMO inhibitor glasdegib were recently presented at the ASH Annual Meeting (13). Several clinical trials using the SMO inhibitor LDE225 are ongoing including a phase I study combining LDE225 with azacitidine or decitabine in myeloid malignancies (NCT02129101). A phase II study with LDE225 in acute leukemia and a phase I study with LDE225 in combination with nilotinib in CML have already been completed but the results are still awaited (NCT01826214 and NCT01456676, respectively) while, disappointingly, a phase II study with GDC-0449 in patients with AML and MDS had to be prematurely terminated due to lower-than-expected efficacy (NCT01880437).

The Hedgehog pathway is essential for normal T-cell development as was shown using mice with defects in HH family members. Mice lacking PTCCH are characterized by a severely affected T-cell development resulting in thymic atrophy and SHH knockout mice have significantly reduced thymocyte levels during development (14,15).

In a recently published preclinical study, Dagklis and colleagues provide evidence that the HH pathway might represent a valuable therapeutic target (7,10-12). Based on promising preclinical data, first clinical studies investigating the therapeutic potential of HH inhibitors in hematological malignancies are ongoing. Encouraging data from a phase II randomized trial of AML and myelodysplastic syndrome (MDS) patients treated with the SMO inhibitor glasdegib were recently presented at the ASH Annual Meeting (13). Several clinical trials using the SMO inhibitor LDE225 are ongoing including a phase I study combining LDE225 with azacitidine or decitabine in myeloid malignancies (NCT02129101). A phase II study with LDE225 in acute leukemia and a phase I study with LDE225 in combination with nilotinib in CML have already been completed but the results are still awaited (NCT01826214 and NCT01456676, respectively) while, disappointingly, a phase II study with GDC-0449 in patients with AML and MDS had to be prematurely terminated due to lower-than-expected efficacy (NCT01880437).

The Hedgehog pathway is essential for normal T-cell development as was shown using mice with defects in HH family members. Mice lacking PTCCH are characterized by a severely affected T-cell development resulting in thymic atrophy and SHH knockout mice have significantly reduced thymocyte levels during development (14,15).

In a recently published preclinical study, Dagklis and colleagues provide evidence that the HH pathway might represent a valuable therapeutic target (7,10-12). Based on promising preclinical data, first clinical studies investigating the therapeutic potential of HH inhibitors in hematological malignancies are ongoing. Encouraging data from a phase II randomized trial of AML and myelodysplastic syndrome (MDS) patients treated with the SMO inhibitor glasdegib were recently presented at the ASH Annual Meeting (13). Several clinical trials using the SMO inhibitor LDE225 are ongoing including a phase I study combining LDE225 with azacitidine or decitabine in myeloid malignancies (NCT02129101). A phase II study with LDE225 in acute leukemia and a phase I study with LDE225 in combination with nilotinib in CML have already been completed but the results are still awaited (NCT01826214 and NCT01456676, respectively) while, disappointingly, a phase II study with GDC-0449 in patients with AML and MDS had to be prematurely terminated due to lower-than-expected efficacy (NCT01880437).

The Hedgehog pathway is essential for normal T-cell development as was shown using mice with defects in HH family members. Mice lacking PTCCH are characterized by a severely affected T-cell development resulting in thymic atrophy and SHH knockout mice have significantly reduced thymocyte levels during development (14,15).

In a recently published preclinical study, Dagklis and colleagues provide evidence that the HH pathway might represent a valuable therapeutic target (7,10-12). Based on promising preclinical data, first clinical studies investigating the therapeutic potential of HH inhibitors in hematological malignancies are ongoing. Encouraging data from a phase II randomized trial of AML and myelodysplastic syndrome (MDS) patients treated with the SMO inhibitor glasdegib were recently presented at the ASH Annual Meeting (13). Several clinical trials using the SMO inhibitor LDE225 are ongoing including a phase I study combining LDE225 with azacitidine or decitabine in myeloid malignancies (NCT02129101). A phase II study with LDE225 in acute leukemia and a phase I study with LDE225 in combination with nilotinib in CML have already been completed but the results are still awaited (NCT01826214 and NCT01456676, respectively) while, disappointingly, a phase II study with GDC-0449 in patients with AML and MDS had to be prematurely terminated due to lower-than-expected efficacy (NCT01880437).

The Hedgehog pathway is essential for normal T-cell development as was shown using mice with defects in HH family members. Mice lacking PTCCH are characterized by a severely affected T-cell development resulting in thymic atrophy and SHH knockout mice have significantly reduced thymocyte levels during development (14,15).

In a recently published preclinical study, Dagklis and colleagues provide evidence that the HH pathway might represent a valuable therapeutic target (7,10-12). Based on promising preclinical data, first clinical studies investigating the therapeutic potential of HH inhibitors in hematological malignancies are ongoing. Encouraging data from a phase II randomized trial of AML and myelodysplastic syndrome (MDS) patients treated with the SMO inhibitor glasdegib were recently presented at the ASH Annual Meeting (13). Several clinical trials using the SMO inhibitor LDE225 are ongoing including a phase I study combining LDE225 with azacitidine or decitabine in myeloid malignancies (NCT02129101). A phase II study with LDE225 in acute leukemia and a phase I study with LDE225 in combination with nilotinib in CML have already been completed but the results are still awaited (NCT01826214 and NCT01456676, respectively) while, disappointingly, a phase II study with GDC-0449 in patients with AML and MDS had to be prematurely terminated due to lower-than-expected efficacy (NCT01880437).
Dagklis and colleagues further observed that also non-leukemic cells were affected by the activated HH cascade in their mouse model. They could detect higher GLI1 levels in normal T cells and thymic epithelial cells (TECs) which are part of the stromal thymic cells. Interestingly, the TECs showed increased expression of Delta-like 4 (Dll4), Interleukin-7 (IL7) and Vascular Endothelial Growth Factor. In previous studies, it was shown that murine and human primary T-ALL samples require stromal-derived signals such as NOTCH ligands or IL7 for their survival. Therefore the authors proposed that T-ALL cells and TECs might interact in a paracrine manner: the leukemic cells secrete HH ligands that stimulate TECs in the thymus which in turn secrete prosurvival factors for the leukemic cells.

Hedgehog-mediated paracrine interactions between tumor and stroma cells represent an accepted concept in cancer biology. Secretion of HH ligands by tumor cells leading to the HH cascade activation in the tumor stroma which in turn provide protumoral growth factors has been described in many cancer entities (3,4,18). On the other hand, paracrine activation of tumor cells through stromal-derived HH ligands was also observed in several hematological cancers such as AML and CLL (7,10,11,19). For instance, Hedge and colleagues showed that stroma-induced HH signaling could increase the survival of B-cell chronic lymphocytic leukemia (B-CLL) cells, whereas treatment of the coculture with the HH inhibitor cyclopamine abrogated the stroma-induced prosurvival effects. Furthermore, gene expression profiling of primary B-CLL cells revealed that HH signaling molecules, including GLI1 and GLI2, were increased and correlated with the patients’ disease progression (11). Besides, we could recently show that stromal cells contribute to the activated HH signaling in AML by provision of DHH (7).

Dagklis et al. evaluated the potential of a HH pathway blockade in vitro using 9 different T-ALL cell lines. Cells were treated with the SMO inhibitors cyclopamine or GDC-0449 or the GLI inhibitor GANT61. Cyclopamine and GDC-0449 caused a dose-dependent inhibition of proliferation in three out of nine analyzed cell lines while GANT61 was more effective and reduced the cell growth in six out of nine T-ALL cell lines. As already mentioned above, the HH pathway can be activated both in a canonical as well as non-canonical manner (3-5). These data show that the activation of the GLI transcription factors seems to be SMO-independent in a part of T-ALL cells as the inhibition of SMO had no effect in contrast to a direct inhibition of the HH downstream mediator GLI. Several GLI activating signaling cascades have been described including Ras-ERK, TGF-β, or PI3K-AKT (3-5,20). In addition to an autocrine DHH-SMO axis, Decker and colleagues identified a SMO-independent non-canonical activation of the HH cascade through ERK signaling in CLL cells (3). In our previous work, we observed an association between the occurrence of FLT3 mutations and high GLI2 expressions levels in AML patients indicating at a non-canonical activation mechanisms of GLI through FLT3 and its downstream target PI3K (7). Furthermore, the combination of a FLT3 inhibitor and GANT61 as direct GLI inhibitor resulted in significantly increased anti-leukemic effects in FLT3-mutated AML cells compared to single agent treatments [20] and unpublished data]. These data are in line with a study by Lim and colleagues as they observed a shortened AML latency upon combination of FLT3-ITD and with a constitutively active SMO in a leukemic mouse model (21). The PI3K cascade might also represent a potential candidate for the non-canonical HH pathway activation in T-ALL as 5–10% of T-ALL patients harbor deletion mutations of the tumor suppressor PTEN which is a critical negative regulator of PI3K signaling. Whether PI3K, one of the other common or further signaling cascades contribute to the non-canonical HH activation in T-ALL should be investigated in future studies (1). Possible mechanisms of the Hedgehog pathway activation are summarized in Figure 1.

What have we learned from recently published studies about the Hedgehog pathway in cancer? Its central role due to activating mutations in cancers such as basal cell carcinoma or medulloblastoma is known for years now and HH inhibitors already found their way into the clinic. But recent data show that dysregulated HH signaling is not restricted to a limited number of cancer entities. Indeed, it seems to be of crucial importance in nearly every cancer including many types of hematological malignancies which makes it a very promising therapeutic target. But: the HH signaling cascade is far more complex than the classical canonical activation axis via HH ligands, PTCH1, SMO and the GLI transcription factors. On the one hand, the signaling cascade is often activated through paracrine interactions of tumor and stromal cells that involve a multitude of other signaling networks. On the other hand, more and more studies reveal the prominent role of the non-canonical HH signaling cascade in cancer. There seems to be a wide variety of possible SMO-independent activation mechanisms indicating that the direct inhibition
of GLI might represent the preferentially therapeutic target in comparison to SMO. Although quite effective in preclinical models, GLI inhibitors such as GANT58 or GANT61 are unlikely to be clinically evaluated due to their high in vitro and in vivo IC50 values. But at least two other options to inhibit GLI in the clinical setting are available: arsenic trioxide (ATO) and Bromodomain and extraterminal domain (BET) protein inhibitors.

ATO is FDA-approved for the treatment of acute promyelocytic leukemia (APL) due to its binding to the malignant fusion protein PML-RARA and its following degradation (22). But ATO has also been described as direct GLI inhibitor that improved the survival in a murine medulloblastoma model with activated HH pathway signaling (23). Although not primarily tested as GLI inhibitor, ATO is currently evaluated as therapeutic target in a number of hematological malignancies including in addition to APL also AML, CML or MDS (e.g., NCT02339740, NCT02200978, NCT02188706, NCT02190695, NCT02188706).

BET proteins are epigenetic modulators regulating gene transcription through recruitment of regulatory complexes to acetylated chromatin regions (24). BRD4, the most prominent family member, was shown to regulate the transcription of important proto-oncogenes. Interestingly, BRD4 was recently identified as regulator of GLI1 and GLI2 (25). Preclinical data revealed the potential of BRD4 inhibitors in hematological malignancies (26,27), that could be strengthened by first clinical results in AML (28). As part of the observed effects is likely to origin from the inhibition of GLI, BRD4 inhibitors should be considered as treatment approach in hematological malignancies including the subgroup of T-ALL patients with an activated HH signaling cascade.

Taken together, patients with hematological malignancies including the subgroup of T-ALL patients with an activated HH signaling cascade might benefit from HH-targeting therapies. Due to the growing evidence of SMO-independent non-canonical HH pathway activation in cancer, GLI inhibitors such as ATO or BRD4 inhibitors

**Figure 1** General mechanisms of the hedgehog pathway activation in tumor cells. The hedgehog pathway can be activated through different mechanisms in cancer cells including an autocrine stimulation loop. On the other hand, the HH signaling cascade can be triggered through paracrine interactions between tumor and stromal cells. HH ligands (HH) can either be provided by stromal cells resulting in activation of the canonical HH cascade in the tumor cells, or the cancer cells produce the HH ligands thereby stimulating the pathway in the stroma. In response, the stromal cells secrete protumoral growth factors (GF) binding to receptor tyrosine kinases (RTK) or other receptors on the tumor cells. Furthermore, the HH pathway can be activated through several non-canonical mechanisms including receptor tyrosine kinases and their intracellular downstream mediators. SMO antagonists (SMOi) can be applied to inhibit the canonical HH axis while they are ineffective in blocking non-canonical HH signals. Arsenic trioxide (ATO) or BET protein inhibitors (BETi) function as GLI inhibitors either by direct binding or by preventing transcription of GLI, respectively, therefore representing clinically applicable alternatives to SMO antagonists.
should be the substances of choice.

Acknowledgements

None.

Footnote

Conflicts of Interest: JW and WF: Inventorship on patents held by Amgen Research (Munich) GmbH/Amgen Inc., WF: Travel grant, advisory board and research funding by Amgen Inc., travel grant and advisory board by TEVA GmbH, advisory board: Ariad/Incyte Inc., travel grant by Gilead Inc., research funding by Pfizer Inc.

References


